The explosive adoption of GLP-1 medications like semaglutide and tirzepatide for weight management has created an urgent need for clinical guidance that goes beyond simply prescribing these drugs. While these therapies deliver unprecedented weight loss results, their gastrointestinal side effects and potential nutritional complications require sophisticated supportive care strategies that most healthcare providers lack training to implement effectively.
An international panel of physicians, researchers, and dietitians used a modified Delphi consensus process to establish 52 specific clinical recommendations addressing the nutritional and lifestyle management challenges accompanying GLP-1-based obesity treatment. The guidelines systematically address four critical domains: nutritional optimization during rapid weight loss, body composition preservation, physical activity integration, and management of common adverse effects including nausea, vomiting, diarrhea, and constipation.
This represents the most comprehensive clinical framework available for healthcare providers navigating the complex intersection of pharmacological weight loss and nutritional medicine. The timing proves crucial as millions of adults begin long-term GLP-1 therapy without adequate supportive care protocols. The consensus emerges from a notable evidence gap—despite the medications' transformative impact, rigorous studies on optimal nutritional support remain scarce, necessitating expert consensus to fill the clinical void. For health-conscious adults considering or currently using these therapies, the guidelines offer the first systematic approach to maximizing benefits while minimizing risks. The framework acknowledges that successful long-term outcomes depend not just on the medication's metabolic effects, but on comprehensive lifestyle integration strategies that preserve lean muscle mass and optimize nutritional status during the weight loss process.